Search Clinical Trials in the European Union
Duration
Visits
Phase
Intake methods
Standard Medicines
Drugs
Locations
Clinical Specialty
81-100 of 1,782 trials
Skin and Nail Candidiasis≤3 monthsConfirmation phase (III)≤5 visitsStandard MedicinesDermatologyInfectious Diseases
ALK-positive Anaplastic Large Cell Lymphoma>2 yearsConfirmation phase (III)>20 visitsNo PlaceboStandard MedicinesOncologyPediatrics
Advanced Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)Confirmation phase (III)Standard MedicinesPartially RemoteOncology
Chronic Kidney DiseaseUncontrolled Hypertension>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCardiologyNephrology
Breast Cancer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesEndocrinologyOncology
Non-small Cell Lung Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteOncology
Acute Myocarditis>2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesCardiologyInternal Medicine
Dupuytren's Contracture>2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesDermatologyOrthopedics and Traumatology
Richter's Syndrome1-2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesHematologyOncology
Atrial Fibrillation with Chronic Kidney Disease Stage 5>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCardiologyInternal MedicineNephrology
Kidney Transplant>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteInternal MedicineNephrology
Major Depressive Disorder≤3 monthsConfirmation phase (III)6-10 visitsStandard MedicinesCost ReimbursementPsychiatry
Type 2 Diabetes and Gestational Diabetes≤3 monthsMonitoring phase (IV)No PlaceboStandard MedicinesEndocrinologyPediatrics
Peripheral T-cell Lymphoma>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesHematologyOncology
Irritable Bowel Syndrome3-6 monthsConfirmation phase (III)≤5 visitsStandard MedicinesGastroenterologyInternal Medicine
Generalized Lipodystrophy1-2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteDermatologyEndocrinology